From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center

Advertisement

BMJ

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial

ESMO Congress 2023 Abstract

386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Current Treatment Options in Oncology

Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer

JAMA Oncology

Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer

OncLive

Frontline zanidatamab plus docetaxel yields antitumor activity, safety in advanced HER2+ breast cancer

Targeted Oncology

Tucatinib plus T-DM1 lowers risk of progression or death in HER2+ mBC

Clinical Breast Cancer

Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

ESMO Open

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

Scientific Reports

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

2023 ASCO Annual Meeting Abstract

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1014

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study

2023 ASCO Annual Meeting Abstract

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

2023 ASCO Annual Meeting Abstract

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

2023 ASCO Annual Meeting Abstract

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial

2023 ASCO Annual Meeting Abstract

An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03

JCO Oncology Practice

Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer

Future Oncology

Margetuximab in HER2-positive metastatic breast cancer

The Oncologist

Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastatic breast cancer after tyrosine kinase inhibitors treatment

Annals of Oncology

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study

The Lancet

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Journal of the Advanced Practitioner in Oncology

Advancing the care of women with HER2-positive metastatic breast cancer

JCO Oncology Practice

Real-world first-line use of pertuzumab with different taxanes for human epidermal growth factor receptor 2–positive metastatic breast cancer: A comparative effectiveness study using US electronic health records

Frontiers in Pharmacology

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

Cancers

HER2-positive metastatic breast cancer: Available treatments and current developments

BMC Medicine

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database

Frontiers in Pharmacology

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-positive metastatic breast cancer

Clinical Cancer Research

Phase I study and cell-free DNA analysis of T-DM1 and metronomic temozolomide for secondary prevention of HER2-positive breast cancer brain metastases

OncLive

ARX788 meets PFS end point in HER2+ metastatic breast cancer

Translational Cancer Research

Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis

Acta Oncologica

A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients

Breast Cancer Research and Treatment

Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer

Breast Cancer

Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort

European Journal of Medical Research

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Cancers

A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer

Cancers

Systemic therapy for HER2-positive metastatic breast cancer: Current and future trends

Frontiers in Oncology

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review

Clinical Breast Cancer

A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases

The ASCO Post

T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer

Targeted Oncology

Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

Oncology Nursing News

DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Cancer Network

Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Journal of Clinical Oncology

Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial

ESMO Congress 2022 Abstract

Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

ESMO Congress 2022 Abstract

Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer

ESMO Congress 2022 Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

Nature Reviews Drug Discovery

Targeting HER2-positive breast cancer: advances and future directions

ERBB2 Mutation in HER2-Nonamplified Breast Cancer

Managing Cardiotoxicity Associated With HER2-Targeted Therapy

ER+/PR+ HER2+ Breast Cancer With Brain Metastases